Tavo103 / Tavotek - LARVOL DELTA

Discovery and Phase 1 study of a novel monoclonal antibody against human IL-1β for the treatment of IL-1β-mediated diseases. (PubMed, Clin Exp Immunol) - "In a Phase 1 study, TAVO103A was found to be safe, well tolerated, and demonstrated a median half-life of 63 days in healthy subjects. By recognizing a different epitope, TAVO103A provided more potent neutralization of IL-1β activities, a longer circulating half-life, and improved safety profiles compared to canakinumab, positioning it to be a potential best-in-class therapeutic option for various IL-1β-mediated diseases."

Journal • P1 data • Atherosclerosis • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Oncology • IL1B

Study of TAVO103A in Healthy Volunteers (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Tavotek Biotherapeutics | Active, not recruiting ➔ Completed

Trial completion

Study of TAVO103A in Healthy Volunteers (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Tavotek Biotherapeutics | Trial completion date: Mar 2023 ➔ Jun 2023 | Trial primary completion date: Nov 2022 ➔ Apr 2023

Trial completion date • Trial primary completion date

Study of TAVO103A in Healthy Volunteers (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Tavotek Biotherapeutics | Not yet recruiting ➔ Active, not recruiting

Enrollment closed

Study of TAVO103A in Healthy Volunteers (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Tavotek Biotherapeutics

New P1 trial